SELLAS Life Sciences Touts Encouraging Preclinical Data For Candidate For Aggressive Form Of Prostate Cancer
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from a new preclinical in vitro study for its highly selective…
Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein for muco-obstructive lung diseases,…
Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment
iVeena Delivery Systems Inc has entered into a strategic licensing agreement with Glaukos Corporation (NYSE:GKOS), granting an exclusive global license to develop and…
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Petco Health Disappoints With Smaller Than Expected Q2 Profits, Annual Guidance
Petco Health And Wellness Company Inc’s (NASDAQ:WOOF) Q2 sales increased 3.2% Y/Y to $1.48 billion, missing the consensus of $1.49…
Integra LifeSciences Recalls CereLink Intracranial Pressure Monitors, Revises Guidance
Integra LifeSciences Holdings Corporation (NASDAQ:IART) initiated an immediate voluntary removal of all CereLink intracranial pressure monitors after customer reports about monitors…
Ainos Seeks FDA Nod For Mid-Stage Covid-19 Study
Ainos, Inc. (NASDAQ: AIMD) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its drug candidate VELDONA, for treatment of mild symptoms related to COVID-19.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck‘s (NYSE:MRK) lead asset MK-2060…
Boxed Warnings May Not Hinder This Depression Drug’s Broad Market Penetration, Analyst Says
Last week, Axsome Therapeutics Inc’s (NASDAQ:AXSM) major depression candidate received the much-awaited FDA approval. HC Wainwright notes that the approval comes roughly…
Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why
Mizuho updated the price target for Cerevel Therapeutics Holdings Inc (NASDAQ:CERE) from $27 to $32 keeping the Neutral rating. The updated model…